A vote to forgo public hearings in a controversial Parkinson’s linked chemical inquiry has raised the ire of advocates and neurologists who claim industry has been prioritised over the public.

A vote to forgo public hearings in a controversial Parkinson’s linked chemical inquiry has raised the ire of advocates and neurologists who claim industry has been prioritised over the public.